Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.52 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.52 |
| ▸ | TACR2 | P21452 | 3/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | NMBR | P28336 | 1/20 | 0.49 |
| ▸ | GRPR | P30550 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089689 | 0.91 | CXCR4 (0.57) | TACR1TACR2CXCR4 | |
| SCHEMBL3089699 | 0.91 | CXCR4 (0.57) | TACR1TACR2CXCR4 | |
| SCHEMBL29463731 | 0.89 | CXCR4 (0.58) | C5AR1CXCR4 | |
| SCHEMBL14583957 | 0.86 | TACR2 (0.52) | TACR1TACR2CAPN1CTSBCXCR4 | |
| SCHEMBL29488759 | 0.85 | TACR1 (0.57) | TACR1NTSR1NTSR2AGTR2AGTR1 | |
| Teprotide SCHEMBL613757 | 0.85 | GNRHR (0.57) | TACR1CAPN1CTSB | |
| SCHEMBL29394387 | 0.84 | TACR1 (0.57) | TACR1NTSR1NTSR2AGTR2AGTR1 | |
| SCHEMBL8937035 | 0.83 | CXCR4 (0.56) | TACR1TACR2C5AR1CXCR4 | |
| SCHEMBL9740766 | 0.82 | CXCR4 (0.54) | TACR2CXCR4 | |
| SCHEMBL9740739 | 0.82 | CXCR4 (0.54) | TACR2CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312685-A1 | Bi-Peptide with Affinity to Extracellular Matrix Proteins or Cells and to Growth Factors for Tissue Healing and Regeneration | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2023-10-05 | — | — | US | claimed |
| CN-116747349-A | Porous microsphere for injection, preparation method and application thereof | 广州远想医学生物技术有限公司 | 2023-09-15 | — | — | CN | claimed |
| EP-3490585-B1 | IMMUNOMODULATORY POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | JUNO THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | claimed |
| CN-113398325-B | Fibrous membrane for enhancing screw stability and inducing bone regeneration and preparation method thereof | 叶川 | 2023-04-21 | — | — | CN | claimed |
| EP-3349811-B1 | PEPTIDE FOR COATING SURFACES | UNIV LEIPZIG (DE) | 2023-04-12 | — | — | EP | claimed |
| CN-114504685-A | Guide film and preparation method thereof | 无锡领缔生物科技有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-20260137836-A1 | MAGNETICALLY-ALIGNED SYNTHETIC EXTRACELLULAR MATRIX FIBERS WITHIN HYDROGEL | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4725960-A2 | SWEET PROTEIN FROM TRUFFLE | Mycotechnology, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4171199-B1 | SWEET PROTEIN FROM TRUFFLE | MYCOTECHNOLOGY INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4661692-A2 | HONEY TRUFFLE SWEETENER (HTS) VARIANTS | Mycotechnology, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-116747349-B | Porous microsphere for injection, preparation method and application thereof | 广州远想医学生物技术有限公司 | 2025-12-05 | — | — | CN | disclosed |
| US-12304935-B2 | Immunomodulatory polypeptides and related compositions and methods | JUNO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220356269-A1 | METHOD FOR ISOLATING EXTRACELLULAR VESICLES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-11-10 | — | — | US | disclosed |
| US-20220259386-A1 | SUPRAMOLECULAR HYDROGELS | TECHNISCHE UNIVERSITEIT EINDHOVEN (NL) | 2022-08-18 | — | — | US | disclosed |
| EP-4034646-A1 | METHOD FOR ISOLATING EXTRACELLULAR VESICLES | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022131809-A1 | PROTEIN SUBSTRATE TO BIND GROWTH FACTOR | TME Therapeutics Co., Ltd. (KR) | 2022-06-23 | — | — | WO | disclosed |
| US-20220183333-A1 | SWEET PROTEIN FROM TRUFFLE | Mycotechnology, Inc. (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114504685-A | Guide film and preparation method thereof | 无锡领缔生物科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-11297861-B2 | Sweet protein from truffle | Mycotechnology, Inc. (US) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | NES, CDH1, SHH | TACR1 2711/4885NTSR1 456/4885NTSR2 494/4885 |
| US-20220259386-A1 | SUPRAMOLECULAR HYDROGELS | UROD, FGB, UACA | TACR1 3539/4885NTSR1 4032/4885NTSR2 4517/4885 |
| US-20260137836-A1 | MAGNETICALLY-ALIGNED SYNTHETIC EXTRACELLULAR MATRIX FIBERS WITHIN HYDROGEL | COL14A1, COL1A1, COL2A1 | TACR1 4869/4885NTSR1 4288/4885NTSR2 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.